Randomized, double-blind, multicenter trial comparing clinafloxacin with imipenem as empirical monotherapy for febrile granulocytopenic patients

Clinical Infectious Diseases

Volumn 32, Issue 3, 2001, Pages 381-390

  Winston, D J ^a   Lazarus, H M ^a   Beveridge, R A ^a   Hathorn, J W ^a   Gucalp, R ^a   Ramphal, R ^a   Chow, A W ^a   Ho, W G ^a   Horn, R ^a   Feld, R ^a   Louie, T J ^a   Territo, M C ^a   Blumer, J L ^a   Tack, K J ^a  

^a UCLA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CILASTATIN PLUS IMIPENEM; CLINAFLOXACIN; IMIPENEM;

ADULT; AGED; ANTIBIOTIC SENSITIVITY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; GRANULOCYTOPENIA; HUMAN; HYPOGLYCEMIA; INFECTION; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SEIZURE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AGRANULOCYTOSIS; ANTI-INFECTIVE AGENTS; BLOOD CELL COUNT; CANADA; DOUBLE-BLIND METHOD; FEMALE; FLUOROQUINOLONES; HUMANS; IMIPENEM; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; THIENAMYCINS; TREATMENT OUTCOME; UNITED STATES;

EID: 0035116101     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/318500     Document Type: Article

References (54)

1. 1997 Guidelines for the use of antimicrobial agents in neutropenic patients
2. A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia
3. Ceftazidime compared with piperacillin and tobramycin for the empiric treatment of fever in neutropenic patients with cancer: A multicenter randomized trial
4. Imipenem/cilastatin versus amikacin plus piperacillin in the treatment of infections in neutropenic patients: A prospective, randomized multi-clinic study
5. β-Lactam antibiotic therapy in febrile granulocytopenic patients: A randomized trial comparing cefoperazone plus piperacillin, ceftazidime plus piperacillin, and imipenem alone
6. A comparison of imipenem to ceftazidime with or without amikacin as empiric therapy in febrile neutropenic patients
7. Monotherapy for fever and neutropenia in cancer patients: A randomized comparison of ceftazidime versus imipenem
8. Randomized comparison of sulbactam/cefoperazone with imipenem as empirical monotherapy for febrile granulocytopenic patients
9. Cefepime versus imipenem-cilastatin as empirical monotherapy in 400 febrile patients with short duration neutropenia
10. Open randomized study of cefepime versus piperacillin-gentamicin for treatment of febrile neutropenic cancer patients
11. Equivalent efficacies of meropenem and ceftazidime monotherapy of febrile granulocytopenic patients
12. Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer
13. Vancomycin is not an essential component of the initial empiric treatment regimen for febrile neutropenic patients receiving ceftazidime: A randomized prospective study
14. Ceftazidime plus amikacin versus ceftazidime plus vancomycin as empiric therapy in febrile neutropenic children with cancer
15. Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer
16. β-Lactam-resistant Enterobacter bacteremia in febrile neutropenic patients receiving monotherapy
17. Imipenem or cefoperazone-sulbactam combined with vancomycin for therapy of presumed or proven infection in neutropenic cancer patients
18. Cefepime/amikacin versus ceftazidime/amikacin as empirical therapy for febrile episodes in neutropenic patients: A comparative study
19. β-Lactam allergy
20. The association between antecedent vancomycin treatment and hospital-acquired vancomycin-resistant enterococci: A meta-analysis
21. In vitro activity of PD 127391, an enhanced-spectrum quinolone
22. In vitro activity of clinafloxacin, trovafloxacin, and ciprofloxacin
23. Comparative activities of clinafloxacin against gram-positive and gram-negative bacteria
24. Use of quinolone antimicrobial agents in immunocompromised patients
25. Management of fever in patients with cancer and treatment-induced neutropenia
26. Ciprofloxacin/piperacillin vs. tobramycin/piperacillin as empiric therapy for fever in neutropenic cancer patients, a randomized double-blind trial
27. Ceftazidime versus imipenem-cilastatin as initial monotherapy for febrile neutropenic patients
28. Intravenous ciprofloxacin for infections in cancer patients
29. A randomized trial of high-dose ciprofloxacin versus azlocillin and netilmicin in the empirical therapy of febrile neutropenic patients
30. Prospective randomized evaluation of ciprofloxacin versus piperacillin plus amikacin for empiric antibiotic therapy of febrile granulocytopenic cancer patients with lymphomas and solid tumors
31. Randomized comparison of oral ofloxacin alone with combination of parenteral antibiotics in neutropenic febrile patients
32. Feasibility, of outpatient management of fever in cancer patients with low-risk neutropenia: Results of a prospective randomized trial
33. Design, analysis, and reporting of clinical trials on the empirical antibiotic management of the neutropenic patient
34. Evaluation of new anti-infective drugs for the treatment of febrile episodes in neutropenic patients
35. New uses for new and old quinolones and the challenge of resistance
36. Bacteremia due to viridans streptococci in neutropenic patients: A review
37. Emergence of fluoroquinolone-resistant Escherichia coli at a cancer center
38. Temafloxacin syndrome: Review of 95 cases
39. Increase in insulin release from rat pancreatic islets by quinolone antibiotics
40. Membrane and DNA damage photosensitized by fluoroquinolone antimicrobials agents: A comparative screening
41. The medical course of cancer patients with fever and neutropenia: Clinical identification of a low-risk subgroup at presentation
42. A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy
43. Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy
44. Levofloxacin. A review of its antibacterial activity, pharmacokinetics, and therapeutic efficacy